Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrates that a novel autologous hair follicle-derived epithelial sheet can effectively repigment skin in patients with stable vitiligo, offering a potential new treatment option.

In this study, researchers detailed various surgical techniques for treating vitiligo, including tissue grafting and cell transplantation. They highlighted recent advancements and emphasized the need for future studies to explore therapeutic mechanisms and identify biomarkers to enhance surgical efficacy.

This article reviews the causes and current treatment options for androgenetic alopecia, reporting no new clinical findings and highlighting the need for more therapeutic choices.

This article discusses the challenges of treating androgenetic alopecia due to limited approved medications, potential side effects, and unmet expectations and reports no new clinical results.

This review discusses Amphiregulin (AREG) as a potential target for treating fibrotic disorders and cancer, highlighting its role in disease progression and promising results in preclinical studies and early trials.

This report details the case of an 11-year-old girl with APECED syndrome carrying a unique homozygous mutation in the AIRE gene, the first of its kind documented.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This review highlights the potential of amphiregulin as a therapeutic target, noting its role in both fibrotic and malignant diseases, and discusses promising early findings but reports no new clinical results.

This study found that applying a 1% cetirizine solution daily for 16 weeks resulted in a statistically significant increase in hair count among men with androgenetic alopecia, although improvements in global photographs were less pronounced, highlighting the need for larger studies to confirm these findings.

This letter to the editor discusses the use of topical cetirizine 1% for treating androgenetic alopecia but reports no new clinical outcomes.

This letter to the editor discusses patient perspectives on androgenetic alopecia treatment at a tertiary dermatology center in Singapore, though results or specific findings are not reported in the abstract.

This article reviews androgenetic alopecia and its effects but reports no new clinical results, highlighting that current treatments offer only temporary therapeutic benefits.

This systematic review explored the potential of cetirizine, an anti-inflammatory antihistamine, as a complementary treatment for androgenetic alopecia, reporting that it might help prevent hair follicle miniaturization by reducing inflammation and modulating immune activity, without notable side effects.

This study demonstrated that AIRE-deficient rats exhibit key symptoms of APECED, making them a relevant model for exploring potential treatments.

This study investigated AGA professionals' perspectives and found that 42% were misled by commercial influences, underestimated these biases' extent, and faced ethical challenges in treatment due to societal pressures and misinformation, highlighting a need for evidence-based guidance and research scrutiny tools.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

This study found that Ageratum conyzoides extract enhanced hair growth in mice and human follicle cells, showing potential for hormonal modulation, pathway activation, and antioxidant protection; however, further clinical studies are needed to confirm efficacy in humans.

This review discussed the cutaneous manifestations of APECED, highlighting chronic mucocutaneous candidiasis, alopecia areata, and vitiligo, while emphasizing the importance of early detection and monitoring for accurate diagnosis and patient care in various populations.

This study found that Agaricus bisporus-derived β-Glucan particles showed potential as an anticancer, antimicrobial, and antioxidant agent, inducing apoptosis and disrupting mitochondrial membrane potential in cervical cancer HeLa cells.

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

This study found that cedrol nanoemulsions significantly promote hair follicle regeneration and reduce DHT levels in an androgenic alopecia mouse model, suggesting potential efficacy in AGA treatment.

In this study, male participants with early androgenetic alopecia experienced a significant increase in hair growth rate after applying topical lipoid cepharanthine lotion for six months.

In this observational study, AC5 reduced hair loss in 89% of subjects with mild androgenic alopecia, and was well tolerated and appreciated by most participants.

This case report highlights a patient with Ayme-Gripp syndrome, revealing an association between the syndrome and hypothyroidism, and underscores the importance of considering rare genetic conditions in differential diagnoses of endocrinopathies.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This study showed that androgenetic alopecia independently predicted higher mortality from diabetes and heart disease in both men and women, with increased rates in individuals with moderate or severe AGA.

This study found that cell-free fat extract (CEFFE) enhanced hair growth in mice with androgenetic alopecia by increasing hair follicle density and promoting proliferation while regulating the DHT/AR pathway.

In this randomized controlled trial, researchers are assessing the efficacy and safety of acupoint catgut embedding combined with topical 5% minoxidil in treating androgenetic alopecia among 70 men, with primary outcomes focusing on changes in hair count after 24 weeks of treatment.